Jane Street Group, LLC Metacrine, Inc. Transaction History

Jane Street Group, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.35 - $0.46 $29,737 - $39,083	-84,964 Reduced 49.02%	88,364 $39,000
Q3 2022 Nov 14, 2022	BUY	$0.43 - $0.55 $74,531 - $95,330	173,328 New	173,328 $84,000
Q3 2022 Nov 14, 2022	BUY	$0.43 - $0.55 $74,531 - $95,330	173,328 New	173,328 $84,000
Q1 2022 May 17, 2022	SELL	$0.43 - $0.7 $29,671 - $48,302	-69,003 Closed	0 $0
Q4 2021 Feb 15, 2022	BUY	$0.64 - $3.83 $44,161 - $264,281	69,003 New	69,003 $47,000

Ticker MTCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,569,500
Description
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.